Loading
Revvity, Inc. Stock: price and insider trades · United States
Revvity, Inc.: what insiders have been doing
Headquartered in Waltham, United States, Revvity, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 11 insiders have disclosed 30 filings since 18 October 2025.
All open-market trades in the period are sales: 2 sales worth €56k, by 2 insiders, with no purchase on record. Biggest ticket of the year: €49k, sold by McMurry-Heath Michelle and made public on 25 February 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 30 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at no purchases and 20 sales. The 10-K for the year ended 28 December 2025 shows 2.86 bn USD of revenue and 241.2 m USD of net income and a dividend of 0.28 USD per share.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
180
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
20 ops. · all time
Who traded when
BuySaleMichelle McMurry-Heath3 sales
Alexis P. Michas1 sale
Gonzales Anita1 sale
Analyst consensus: bullish or bearish?
Analysts rate Revvity, Inc. Buy (bullish), based on 15 analysts. Average price target: US$147.53.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,224 of 24,148 companies
43.4
score / 100
Value37
Quality50
FCF yld3.0%
Earn yld1.4%
EV/EBITDA26.7x
ROE3.2%
Gross mgn55%
Net mgn8.4%
Debt/EBITDA4.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$152.64
Analyst consensus
15 analystsBuy
US$110.00Target US$147.53(-3%)US$175.00
Income statement
RevenueUS$2.9B
Gross profitUS$1.6B55% margin
EBITDAUS$765.8M27% margin
Net incomeUS$241.2M8.2% margin
Valuation
PER (trailing)73.0x
PER (forward)25.9x
P/Book2.4x
Beta1.06
Balance sheet & cash
Market capUS$17B
Total debtUS$3.4B
Free Cash FlowUS$509.4M
Debt / Equity46%
Profitability & ownership
ROE3.2%
ROA2.4%
% insiders0.3%
% institutions103.7%
Last declaration on 1 October 2026
Declarations180 total
84 shares@ US$155.480.0001% mcap10.9% of flowCommonSEC144:0001959173-26-007172
1,631 shares@ US$144.530.0015% mcap47.5% of flowCommonSEC144:0001959173-26-007045
7,330 shares@ US$140.880.0064% mcap28.9% of flowCommonSEC144:0001959173-26-006999
285 shares0Common StockSEC:0001193125-26-365114:0
27,785 shares0Common StockSEC:0001193125-26-355406:0
27,785 shares0Common StockSEC:0001193125-26-355406:1
7,636 shares0Common StockSEC:0001193125-26-354025:0
7,636 shares0Common StockSEC:0001193125-26-354025:1
59,650 shares0Common StockSEC:0001193125-26-354025:2
59,650 shares0Common StockSEC:0001193125-26-354025:3
85 shares@ US$109.480.0001% mcap8.6% of flowCommonSEC144:0001959173-26-005275
80 shares@ US$92.800.0001% mcap6.7% of flowCommon StockSEC:0001193125-26-170346:0
1,600 shares0Common StockSEC:0001193125-26-113918:0
1,721 shares0Common StockSEC:0001193125-26-100118:0
1,862 shares@ US$95.7427.1% of flowCommon StockSEC:0001193125-26-076543:0
600 shares@ US$97.2615.2% of flowCommon StockSEC:0001193125-26-071522:0
1,457 shares@ US$96.0327.3% of flowCommon StockSEC:0001193125-26-059345:0
69 shares@ US$96.035.9% of flowCommon StockSEC:0001193125-26-059344:0
566 shares@ US$96.031.5% of flowCommon StockSEC:0001193125-26-059342:0
1,733 shares@ US$96.034.6% of flowCommon StockSEC:0001193125-26-059340:0
1,031 shares@ US$96.0315.0% of flowCommon StockSEC:0001193125-26-059343:0
6,901 shares@ US$96.0312.5% of flowCommon StockSEC:0001193125-26-059339:0
869 shares@ US$101.130.0007% mcap2.4% of flowCommon StockSEC:0001193125-26-041151:0
708 shares@ US$101.1314.0% of flowCommon StockSEC:0001193125-26-041157:0
359 shares@ US$101.131.0% of flowCommon StockSEC:0001193125-26-041152:0
25 of 180 declarations
About Revvity, Inc.
Revvity, Inc. (ticker: RVTY) is a U.S.-based company listed on the NYSE/NASDAQ markets in the United States. It operates in the health science, diagnostics, and life sciences space, with a business model built around enabling workflows from discovery to development, and from diagnosis to cure. The company was launched in 2023 through the rebranding of PerkinElmer, reflecting a sharper strategic focus on higher-value areas such as translational research, biomarker discovery, diagnostics, and scientific software. Revvity’s headquarters are in Waltham, Massachusetts, and the company serves customers in more than 160 countries with roughly 11,000 employees globally. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx?utm_source=openai))
From an operating standpoint, Revvity is organized around two major pillars: Life Sciences and Diagnostics. Its product and service portfolio includes reagents, consumables, assays, instruments, laboratory services, automation systems, genetic testing, imaging solutions, and software. The company’s Signals software suite is an important differentiator, linking data, workflows, and analytics for biotech, pharma, academia, diagnostic labs, and government customers. Revvity also emphasizes multi-omics, preclinical oncology drug discovery support, viral vector manufacturing, and clinical genetic testing, which broadens the addressable market and makes the business more integrated than a typical single-category tools company. ([revvity.com](https://www.revvity.com/?utm_source=openai))
Read moreShow less
Revvity’s history matters for investors: it inherits the legacy of PerkinElmer, a long-standing scientific instrumentation and diagnostics business. The 2023 name change was not just cosmetic; it signaled a portfolio shift toward scientific solutions with stronger structural demand and more attractive long-term economics. For international investors, that means Revvity should be viewed as a specialized healthcare technology supplier rather than a traditional pharma company. Its customer base is diversified across pharmaceutical and biotechnology companies, diagnostic laboratories, universities, and public-sector institutions. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx?utm_source=openai))
Competitive positioning is anchored in breadth and workflow coverage. Revvity can provide tools across the research-to-diagnosis continuum, which creates cross-selling opportunities and supports customer stickiness. The company’s global footprint is also meaningful: it markets products and services in more than 160 countries, with a substantial presence in North America, Europe, and Asia. That geographic diversification reduces dependence on any single end market, although demand remains tied to R&D budgets, clinical testing activity, and spending cycles in life science tools. ([sec.gov](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/revv-20241229.htm?utm_source=openai))
Recent developments have centered on execution, product innovation, and portfolio optimization. Revvity reported first-quarter 2026 results and continued to highlight its strategic focus on health science solutions. In 2025, management guided full-year revenue in the approximately $2.83 billion to $2.88 billion range in its quarterly communications, while maintaining an organic growth outlook of 2% to 4% in certain periods. That points to a company with moderate top-line growth, supported by recurring consumables and software exposure, but still sensitive to currency movements and the timing of instrument demand. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2026/Revvity-Announces-Financial-Results-for-the-First-Quarter-of-2026/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
